• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Fonar returns to profitability in third quarter

Article

MRI vendor Fonar is back in the black for the first time sinceMarch 1994. The Melville, NY, company posted financial resultsfor its third fiscal quarter (end-March) that show net incomeof $1.9 million, compared with a net loss of $903,000 in the

MRI vendor Fonar is back in the black for the first time sinceMarch 1994. The Melville, NY, company posted financial resultsfor its third fiscal quarter (end-March) that show net incomeof $1.9 million, compared with a net loss of $903,000 in the sameperiod last year. The growth in profits came as Fonar's revenuesslipped to $3 million in the most recent quarter, compared with$3.2 million in the third quarter of 1995.

Fonar did not indicate how it was able to record such a rapidprofit turnaround on lower sales. It is possible that the companyis enjoying the benefits of payments related to MRI patent litigationit has settled with Hitachi and Philips, but Fonar declined tostate whether it received any such payments in its most recentquarter.

Recent Videos
Computed Tomography Study Shows Emergence of Silicosis in Engineered Stone Countertop Workers
Can an Emerging AI Software for DBT Help Reduce Disparities in Breast Cancer Screening?
Skeletal Muscle Loss and Dementia: What Emerging MRI Research Reveals
Magnetoencephalopathy Study Suggests Link Between Concussions and Slower Aperiodic Activity in Adolescent Football Players
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Assessing a Landmark Change in CMS Reimbursement for Diagnostic Radiopharmaceuticals
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Can 18F-Floutufolastat Bolster Detection of PCa Recurrence in Patients with Low PSA Levels After Radical Prostatectomy?
Related Content
© 2024 MJH Life Sciences

All rights reserved.